文献速递泌尿男性生殖肿瘤

双周与三周卡巴他赛方案在老年转移性去势抵抗性前列腺癌患者中的比较:CABASTY 3期随机临床试验

Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

CABASTY 3期随机试验在法国和德国25个中心纳入196例65岁及以上、已接受多西他赛和至少一种新型雄激素受体靶向药物的进展性转移性去势抵抗性前列腺癌患者,比较双周卡巴他赛16 mg/m2联合G-CSF与三周卡巴他赛25 mg/m2联合G-CSF。结果显示双周方案显著降低3级及以上中性粒细胞减少和/或中性粒细胞减少并发症发生率(5.1% vs 62.5%),临床结局相当。

要点

  • 双周卡巴他赛16 mg/m2联合G-CSF较三周25 mg/m2方案显著降低3级及以上中性粒细胞减少和/或中性粒细胞减少并发症(5.1% vs 62.5%,OR 0.03,95%CI 0.01-0.08,P<.001)。
  • 两组相对剂量强度相当(三周组中位92.7% vs 双周组92.8%)。
  • 3级及以上不良事件三周组72.9% vs 双周组56.1%;三周组1例死于中性粒细胞减少并发症。

核心结论

  • 在65岁及以上转移性去势抵抗性前列腺癌患者中,与标准三周方案相比,双周卡巴他赛16 mg/m2联合G-CSF使3级及以上中性粒细胞减少和/或中性粒细胞减少并发症发生风险降低约12倍,临床结局相当。
  • 作者认为,对于标准方案不合适的65岁及以上转移性去势抵抗性前列腺癌患者,应提供双周卡巴他赛16 mg/m2方案。

研究设计与样本

  • 前瞻性3期随机临床试验,在法国18个中心和德国7个中心开展,2017年5月5日至2021年1月7日入组196例65岁及以上进展性转移性去势抵抗性前列腺癌患者。
  • 所有患者均接受过多西他赛和至少1种新型雄激素受体靶向药物治疗。
  • 患者按1:1随机分配至双周卡巴他赛16 mg/m2联合G-CSF和每日泼尼松龙组(试验组)或三周卡巴他赛25 mg/m2联合G-CSF和每日泼尼松龙组(对照组)。
  • 主要终点为最低点时测得的3级及以上中性粒细胞减少和/或中性粒细胞减少并发症的发生。

主要发现

  • 196例患者中三周卡巴他赛25组97例、双周卡巴他赛16组99例;中位(IQR)年龄74.6(70.4-79.3)岁,181例(92.3%)ECOG体能状态评分为0或1。
  • 中位(IQR)随访时间31.3(22.5-37.5)个月。
  • 相对剂量强度两组相当:三周卡巴他赛25组中位(IQR)92.7%(83.7%-98.9%)vs 双周卡巴他赛16组92.8%(87.0%-98.9%)。
  • 3级及以上中性粒细胞减少和/或中性粒细胞减少并发症发生率三周卡巴他赛25组60/96(62.5%)vs 双周卡巴他赛16组5/98(5.1%),比值比0.03(95%CI 0.01-0.08),P<.001。
  • 3级及以上不良事件三周卡巴他赛25组70/96(72.9%)vs 双周卡巴他赛16组55/98(56.1%);三周卡巴他赛25组1例患者死于中性粒细胞减少并发症。

关键数值与推荐

  • 3级及以上中性粒细胞减少和/或中性粒细胞减少并发症发生率:三周卡巴他赛25组62.5% vs 双周卡巴他赛16组5.1%,OR 0.03(95%CI 0.01-0.08),P<.001。
  • 3级及以上不良事件发生率:三周卡巴他赛25组72.9% vs 双周卡巴他赛16组56.1%。
  • 相对剂量强度中位(IQR):三周卡巴他赛25组92.7%(83.7%-98.9%)vs 双周卡巴他赛16组92.8%(87.0%-98.9%)。

临床怎么用

  • 作者认为,对于标准三周卡巴他赛方案不合适的65岁及以上转移性去势抵抗性前列腺癌患者,应提供双周卡巴他赛16 mg/m2联合G-CSF方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Many patients 65 years or older with metastatic castration-resistant prostate cancer (mCRPC) are denied taxane chemotherapy because this treatment is considered unsuitable. OBJECTIVE: To determine whether biweekly cabazitaxel (CBZ), 16 mg/m2 (biweekly CBZ16), plus prophylactic granulocyte colony-stimulating factor (G-CSF) at each cycle reduces the risk of grade 3 or higher neutropenia and/or neutropenic complications (eg, febrile neutropenia, neutropenic infection, or sepsis) compared with triweekly CBZ, 25 mg/m2 (triweekly CBZ25), plus G-CSF (standard regimen). DESIGN, SETTING, AND PARTICIPANTS: A total of 196 patients 65 years or older with progressive mCRPC were enrolled in this prospective phase 3 randomized clinical trial conducted in France (18 centers) and Germany (7 centers) between May 5, 2017, and January 7, 2021. All patients had received docetaxel and at least 1 novel androgen receptor-targeted agent. INTERVENTIONS: Patients were randomly assigned 1:1 to receive biweekly CBZ16 plus G-CSF and daily prednisolone (experimental group) or triweekly CBZ25 plus G-CSF and daily prednisolone (control group). MAIN OUTCOME AND MEASURES: The primary end point was the occurrence of grade 3 or higher neutropenia measured at nadir and/or neutropenic complications. RESULTS: Among 196 patients (97 in the triweekly CBZ25 group and 99 in the biweekly CBZ16 group), the median (IQR) age was 74.6 (70.4-79.3) years, and 181 (92.3%) had an Eastern Cooperative Oncology Group performance status of 0 or 1. The median (IQR) follow-up duration was 31.3 (22.5-37.5) months. Relative dose intensities were comparable between groups (median [IQR], 92.7% [83.7%-98.9%] in the triweekly CBZ25 group vs 92.8% [87.0%-98.9%] in the biweekly CBZ16 group). The rate of grade 3 or higher neutropenia and/or neutropenic complications was significantly higher with triweekly CBZ25 vs biweekly CBZ16 (60 of 96 [62.5%] vs 5 of 98 [5.1%]; odds ratio, 0.03; 95% CI, 0.01-0.08; P < .001). Grade 3 or higher adverse events were more common with triweekly CBZ25 (70 of 96 [72.9%]) vs biweekly CBZ16 (55 of 98 [56.1%]). One patient (triweekly CBZ25 group) died of a neutropenic complication. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, compared with the standard regimen, biweekly CBZ16 plus G-CSF significantly reduced by 12-fold the occurrence of grade 3 or higher neutropenia and/or neutropenic complications, with comparable clinical outcomes. The findings suggest that biweekly CBZ16 regimen should be offered to patients 65 years or older with mCRPC for whom the standard regimen is unsuitable. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02961257.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Oudard S, Ratta R, Voog E, et al. Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37883073. doi:10.1001/jamaoncol.2023.4255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。